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TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3
and Functions as a T Cell Costimulator
that some members of this subgroup of receptors, such
as Fas, also have the ability to positively affect T cell
activation. A third group of receptors has also been
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Joe X.H. Zhou, Yun Hee Cho, Stephen Ullrich, described. The members of this group, which include
DcR1, DcR2, OPG, and TR6 (also called DcR3), havePalanisamy Kanakaraj, Jeffrey Carrell,
Ernest Boyd, Henrik S. Olsen, Gang Hu, been named decoy receptors, as they lack a cyto-
plasmic domain and may act as inhibitors by competingLaurie Pukac, Ding Liu, Jian Ni, Sunghee Kim,
Reiner Gentz, Ping Feng, Paul A. Moore, with the signal-transducing receptor for the ligand (Ash-
kenazi and Dixit, 1999). TR6, which exhibits closest ho-Steve M. Ruben, and Ping Wei1
Human Genome Sciences, Inc. mology to OPG, associates with high affinity to FasL
and LIGHT and inhibits FasL-induced apoptosis both inRockville, Maryland 20850
vitro and in vivo (Pitti et al., 1998; Yu et al., 1999; Connolly
et al., 2001). Its role in downregulating immune re-
sponses was strongly suggested by the observation thatSummary
TR6 suppresses T cell responses against alloantigen
(Zhang et al., 2001) and certain tumors overexpress TR6DR3 is a death domain-containing receptor that is
upregulated during T cell activation and whose over- (Pitti et al., 1998; Bai et al., 2000).
DR3 is a DD-containing receptor that shows highestexpression induces apoptosis and NF-B activation in
cell lines. Here we show that an endothelial cell- homology to TNFR1 (Chinnaiyan et al., 1996; Kitson et
al., 1996; Marsters et al., 1996; Bodmer et al., 1997;derived TNF-like factor, TL1A, is a ligand for DR3 and
decoy receptor TR6/DcR3 and that its expression is Screaton et al., 1997; Tan et al., 1997). In contrast to
TNFR1, which is ubiquitously expressed, DR3 appearsinducible by TNF and IL-1. TL1A induces NF-B acti-
vation and apoptosis in DR3-expressing cell lines, to be preferentially expressed by lymphocytes and is
efficiently induced following T cell activation. TWEAK/while TR6-Fc protein antagonizes these signaling
events. Interestingly, in T cells, TL1A acts as a costim- Apo3L was previously shown to bind DR3 in vitro (Mar-
sters et al., 1998). However, more recent work raisedulator that increases IL-2 responsiveness and secre-
tion of proinflammatory cytokines both in vitro and in doubt about this interaction and showed that TWEAK
functions through a TNFR, TweakR, and is able to inducevivo. Our data suggest that interaction of TL1A with
DR3 promotes T cell expansion during an immune re- NF-B and caspase activation in cells lacking DR3
(Schneider et al., 1999; Kaptein et al., 2000; Wiley et al.,sponse, whereas TR6 has an opposing effect.
2001).
In this paper, we describe the identification and char-Introduction
acterization of a ligand, which we have named TL1A,
for both DR3 and TR6/DcR3. TL1A is a longer variantMembers of the TNF and TNFR superfamilies of proteins
are involved in the regulation of many important biologi- of TL1 (also called VEGI), which was previously identified
as an endothelium-derived factor that inhibited endothe-cal processes, including development, organogenesis,
and innate and adaptive immunity (Locksley et al., 2001). lial cell growth in vitro and tumor progression in vivo
(Tan et al., 1997; Zhai et al., 1999a, 1999b; Yue et al.,Interaction of TNF ligands such as TNF, Fas, LIGHT, and
BLyS with their cognate receptor (or receptors) has been 1999). We found that TL1A is the full-length gene product
and is markedly upregulated by TNF and IL-1. We showshown to affect immune responses, as they are able to
activate signaling pathways that link them to the regula- that interaction between TL1A and DR3 in a reconstitu-
ted system or in cells that naturally express DR3 resultstion of inflammation, apoptosis, homeostasis, host de-
fense, and autoimmunity. The TNFR superfamily can in activation of NF-B and apoptosis. TR6 is able to
inhibit these activities by competing with DR3 for TL1A.be divided into two groups based on the presence of
different domains in the intracellular portion of the re- More importantly, we have found that in vitro, TL1A
functions specifically on activated T cells to promoteceptor. One group contains a TRAF binding domain that
enables it to couple to TRAFs (TNFR-associated fac- survival and secretion of proinflammatory cytokines,
and in vivo, it potently enhances acute graft-versus-hosttors); these, in turn, activate a signaling cascade that
results in the activation of NF-B and initiation of tran- reactions.
scription. The second group of receptors is character-
ized by a 60 aa globular structure named death domain Results
(DD). Historically, death domain-containing receptors
have been described as inducers of apoptosis via the TL1A Is a Longer Variant of TL1 (VEGI) and a Member
activation of caspases. These receptors include TNFR1, of the TNF Ligand Superfamily
DR3, DR4, DR5, DR6, and Fas. More recent evidence To identify TNF-like molecules, a database of over three
(Siegel et al., 2000 and references within) has shown million human expressed sequence tag (EST) sequences
was analyzed using the BLAST algorithm. Several EST
clones with high homology to TNF-like molecule 1, TL11Correspondence: ping_wei@hgsi.com
2 These authors contributed equally to this work. (or VEGI), were identified from endothelial cell cDNA
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libraries. Sequence analysis of these cDNA clones re- levels were seen in intestine, lung, spleen, and thymus.
Very little if any was detected in heart, brain, liver, PBL,vealed a 2.02 kb insert encoding an open reading frame
of 251 aa. The predicted protein lacks an N-terminal or adrenal gland (Figure 2A and data not shown). We
did not detect significant levels of TL1A mRNA in anysignal peptide but contains a hydrophobic transmem-
brane region near the 5 end and a carboxyl domain of the cancer cell lines tested, including 293T, HeLa,
Jurkat, Molt4, Raji, IM9, U937, Caco-2, SK-N-MC,that shows highest sequence identity to TNF (24.6%),
followed by FasL (22.9%) and LT (22.2%). Interestingly, HepG2, KS4-1, and GH4C (data not shown).
Although the reported mRNA expression profile ofthe C-terminal 151 aa of this protein (aa 101–251) and
that of TL1 (aa 24–174) are identical, whereas the TL1, detected by Northern hybridization (Tan et al., 1997;
Zhai et al., 1999a), is very similar to that of TL1A, theN-terminal regions share no sequence similarity (Figure
1A). To distinguish it from TL1, we have named it TL1A. Northern probes used for those analyses were derived
from the shared region of TL1A and TL1 and thereforeThe cloned mouse and rat TL1A cDNAs encode proteins
of 252 aa and share 63.7% and 66.1% sequence homol- may have detected the total level of expression of the
two RNA. To analyze the relative abundance of the twoogy to the human counterpart, respectively (Figure 1A).
The presence of in-frame upstream stop codons in hu- RNA species, we used TL1A and TL1-specific primers
and fluorescent probes for conventional and quantita-man, mouse, and rat cDNA clones indicated that these
open reading frames are full length. tive RT-PCR. As shown in Figures 2B and 2C, both meth-
ods yielded a similar result: that TL1A mRNA is the moreThe 2.02 kb TL1A cDNA was blasted against the pub-
lic human genome databases (www.ncbi.nlm.nih.gov/ abundant form. The amount of TL1A-specific mRNA is
at least 15-fold higher than that of TL1. Since TL1A isgenome/guide/human; www.ensembl.org) and was
mapped, as TL1 originally was, to chromosome 9q32 the predominant species of the two RNA and also ap-
pears to be the full-length form, we have focused our(Figure 1B). Detailed sequence alignment revealed that
TL1A is encoded by four coding exons (shaded boxes) study on this form.
To determine if TL1A mRNA levels were inducible,utilizing consensus splicing sites, while TL1 is encoded
by a continuous DNA containing the exon 4 and its 5 HUVEC cells were stimulated with TNF, IL-1, PMA,
bFGF, or IFN. As shown in Figure 2D, PMA and IL-1adjacent intron region (open box). As a result, TL1 lacks a
transmembrane domain and the first conserved  strand rapidly induced high levels of TL1A mRNA, with a peak
in expression reached at 6 hr after treatment. TNF wasseen in other TNF family of ligands. To our surprise, we
found that the 3.3 kb TL1 cDNA matches completely also able to induce TL1A mRNA, and a weak stimulation
by bFGF could be seen at the 6 hr time point. In contrast,a TL1A genomic DNA region of the same length that
contains both the introns and exons (3 and 4) of TL1A IFN may have a negative effect on TL1A expression.
(Figure 1B).
Like most TNF ligands, TL1A exists as a membrane Identification of DR3 and TR6 as Receptors for TL1A
bound protein (Figure 3A, fourth panel) and can also be To identify the receptor for TL1A, we generated a 293F
processed into a soluble form when ectopically ex- stable cell line expressing full-length TL1A on the cell
pressed (data not shown). The N-terminal sequence of surface (Figure 3A, fourth panel). These cells were used
soluble TL1A protein purified from full-length TL1A- to screen the Fc-fusion form of the extracellular domain
transfected 293T cells was determined to be Leu72 (Fig- of TNFR family members, including TNFR1, Fas, HveA,
ure 1A). DR3, DR4, DR5, DR6, DcR1, DcR2, TR6, OPG, RANK,
AITR, TACI, CD40, and OX40. As shown in Figure 3A,
DR3-Fc and TR6-Fc bound efficiently to cells expressingTL1A Is Predominantly Expressed by Endothelial
Cells, Is More Abundant than TL1/VEGI, and Is TL1A (second and third panels) but not to vector control
transfected cells (first panel). In contrast, HveA-Fc (sec-Inducible by TNF and IL-1
The expression pattern of TL1A mRNA was studied us- ond panel) and all the other receptors tested (data not
shown) did not bind to the TL1A-expressing cells. Weing quantitative real-time polymerase chain reaction
(TaqMan) and reverse transcriptase polymerase chain then tested whether TR6 could compete with DR3 for
TL1A binding. When a 2:1 molar ratio of a nontaggedreaction (RT-PCR) (see Experimental Procedures). We
found that TL1A was expressed predominantly by hu- form of TR6 and DR3-Fc was used, no binding of DR3-
Fc was detected on TL1A-expressing cells (third panel).man endothelial cells, including the umbilical vein endo-
thelial cells (HUVEC), the adult dermal microvascular These results demonstrated that both DR3 and TR6 can
bind to the membrane bound form of the TL1A protein.endothelial cells (HMVEC-Ad), and uterus myometrial
endothelial cells (UtMEC-Myo), with highest expression To determine whether TL1A protein could bind to the
membrane bound form of DR3, a Flag-tagged solubleseen in HUVEC (Figure 2A). An 750 bp DNA fragment
was readily amplified from these endothelial cells by form of the TL1A (aa 72–251) protein was tested on cells
transiently transfected with different members of theRT-PCR, indicating the presence of full-length TL1A
transcripts (Figure 2B). Very little expression was seen TNFR family, including TNFR2, LTR, 4-1BB, CD27,
CD30, BCMA, DR3, DR4, DR5, DR6, DcR1, DcR2, RANK,in human aortic endothelial cells (HAEC) or other human
primary cells including adult fibroblasts (NHDF-Ad and HveA, and AITR. We consistently detected binding of
Flag-TL1A but not Flag-TRAIL to cells expressing full-HFL-1), aortic smooth muscle cells (AoSMC), skeletal
muscle cells (SkMC), adult keratinocytes (NHEK-Ad), length or DD-deleted DR3 (Figure 3B and data not shown).
No association was seen with DD-deleted DR5 or anytonsillar B cells, T cells, NK cells, monocytes, or den-
dritic cells. In human tissues, TL1A mRNA was detected of the other receptors tested, demonstrating that TL1A
interacts specifically with membrane-associated DR3.in kidney, prostate, placenta, and stomach, and low
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Figure 1. Sequence and Genomic Structure of TL1A
(A) Amino acid sequence alignment of TL1A from human (h), mouse (m), and rat (r), and human TL1. Identical aa are boxed. Dashes indicate
gaps between regions of homology. The predicted transmembrane domain is underlined, and the potential N-linked glycosylation sites are
in bold. Arrow represents the N-terminal cleavage site of soluble TL1A. Bars above sequences indicate the positions of  strand forming
sequences (labeled A–H) according to the crystal structure of LT (Eck et al., 1992). Alignments were generated using Megalign (Clustal
Method, DNASTAR) software.
(B) Diagram of the TL1A genomic structure. Intron/exon sizes are shown above the DNA. The shaded boxes represent TL1A coding exons
1–4, and the open box depicts the intron region encoding the first 23 aa of TL1. The number of residues encoded by each exon, the genomic
contigs, and BAC clones that contain the genomic DNA are shown. The 3.3 kb TL1 cDNA matches to the 3 region of the genomic DNA is
also shown.
Coimmunoprecipitation studies were also performed Fc and TR6-Fc specifically interacted with Flag-TL1A
(Figure 3C). In contrast, TACI-Fc or Fas-Fc could notto confirm the specific interaction between the soluble
forms of TL1A and the receptors. We found that DR3- immunoprecipitate Flag-TL1A but efficiently bound their
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Figure 2. Expression Analysis of TL1A mRNA
(A) Taqman (quantitative real-time PCR) analysis of TL1A mRNA expression. TL1A-specific primer and fluorescence probe were used. All
values were normalized to 18S ribosomal RNA internal control. Standard deviations were calculated from triplicate reactions. The relative
level of expression was displayed in arbitrary units in which one is equivalent to 1  105 fraction of the 18S RNA amount.
(B) RT-PCR analysis of expression of TL1 and TL1A mRNA in endothelial cells. 0.5 micrograms of total RNA was amplified using gene-specific
sense and antisense primers for TL1 (522 bp product) or TL1A (750 bp product). -actin (600 bp product) was used as internal control. Lane
1, HUVEC; lane 2, HMVEC-Ad; lane 3, UtMVEC-Myo; lane 4, HAEC. TL1 cDNA (C1, 2 pg) and TL1A cDNA (C2, 2 pg) were used as positive
controls. M, 100 bp DNA ladder.
(C) Taqman analysis of TL1 and TL1A mRNA expression in endothelial cells. TL1 or TL1A-specific primer and fluorescence probe were used
and the data were derived from triplicate reactions and analyzed as in (A). Lane 1, HUVEC; lane 2, HMVEC-Ad; lane 3, UtMVEC-Myo; lane 4,
HAEC. The amount of TL1 expression in HUVEC was set as 1.
(D) Inducible expression of TL1A mRNA in HUVEC cells. HUVEC were either untreated (NT) or treated with IL-1 (2 ng/ml), TNF (50 ng/ml),
PMA (100 ng/ml), bFGF (50 ng/ml), or IFN (10 ng/ml) for 1, 6, or 24 hr. TL1A mRNA expression at each time point was analyzed as described
in (A). TL1A level in untreated sample at 1 hr time point was set as 1.
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Figure 3. TL1A Interacts with DR3 and TR6/DcR3
(A) Flow cytometric analyses of TNFR-Fc binding to TL1A-expressing cells. 293F cells stably transfected with vector (Neo, first panel) or full-
length TL1A (second and third panels) were incubated with DR3-Fc, TR6-Fc, or HveA-Fc (negative control) and stained with PE-conjugated
goat anti-human IgG antibody. In the third panel, nontagged TR6, at a 2:1 molar ratio, was used together with DR3-Fc. In the fourth panel,
TL1A cells were stained with TL1A monoclonal Ab 16H02 or a mouse isotype control Ab.
(B) Flow cytometric analyses of binding of Flag-TL1A (aa 72–251) protein to membrane-bound DR3 receptor. 293T cells were transiently
transfected with either vector control (pC4), or DD-deleted mutant DR3 (pC4:DR3DD) or DR5 (pC4:DR5DD). Cells were stained 40 hr later
with either secondary Ab alone (dashed line) or Flag-tagged protein (Flag-TL1A, filled histogram; Flag-TRAIL, dark line) followed by anti-Flag Ab.
(C) Coimmunoprecipitation of DR3-Fc and TR6-Fc with TL1A. Flag-tagged TL1A (aa 72–251) or BlyS (aa 134–285) protein was incubated with
or without recombinant DR3-Fc, TR6-Fc, Fas-Fc, or TACI-Fc protein and precipitated with Protein A-agarose beads. The bound proteins were
analyzed by Western blotting with anti-Flag M2 antibody (upper panel) or with anti-human Fc antibody (lower panel).
known ligands, Flag-BlyS (Figure 3B) and Flag-FasL (not 6.39E 	 05 Ms1 and 4.13E  03M1, respectively. The
average Kd value was 6.45 
 0.2 nM. TL1A was alsoshown), respectively.
To determine the binding affinity of solubleTL1A to examined for its ability to bind to several other TNF-
related receptors (HveA, BCMA, TACI, and TR6). Be-DR3-Fc and TR6-Fc, we performed a BIAcore analysis
using a nontagged TL1A (aa 72–251) protein purified sides DR3, only TR6 was found to exhibit significant and
specific binding to TL1A. The KA and KD values werefrom E. coli. The kinetics of TL1A binding to DR3-Fc
was determined using three different batches of the 1.04E	 06 Ms1 and 1.9E 03 M1, respectively, which
gives a Kd of 1.8 nM. The specificity of binding of TL1ATL1A protein. The KA and KD values were found to be
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to DR3-Fc and TR6-Fc was confirmed by the competi- combinant TL1A (aa 72–251) protein was tested for its
ability to induce proliferation of resting or costimulatedtion of TL1A binding in the presence of excess soluble
receptor-Fc (data not shown). These Kd values for bind- T cells (treated with amounts of anti-CD3 and anti-CD28
that are not sufficient to induce optimal proliferation).ing of TL1A to DR3-Fc and TR6-Fc are comparable to
those determined for other TNFR-ligand interactions. In resting (data not shown) or costimulated T cells, we
did not observe a significant increase in proliferation
over background (Figure 5A, compare the light bars ofInteraction of TL1A with DR3 Induces
untreated versus TL1A-treated samples). Interestingly,Activation of NF-B
cells that were previously treated with TL1A for 72 hrIt was reported previously that ectopic expression of
were able to proliferate better in response to IL-2 com-DR3 results in the activation of the transcription factor
pared to T cells that had not been pretreated with TL1ANF-B (Chinnaiyan et al., 1996; Kitson et al., 1996; Mar-
(Figure 5A, compare the dark bars of untreated versussters et al., 1996; Bodmer et al., 1997). We therefore
TL1A-treated samples), indicating that TL1A increasesdecided to study TL1A-induced signaling in a recon-
the IL-2 responsiveness of costimulated T cells.stitution system in 293T cells in which DR3 and an
As enhanced IL-2 responsiveness has been associ-NF-B-SEAP reporter were introduced by transient
ated with increased IL-2 receptor expression and alteredtransfection. To avoid spontaneous apoptosis or NF-B
cytokine secretion, it was of interest to assess theseactivation caused by DR3 overexpression, we used a
responses on costimulated T cells treated with TL1A.limited amount of DR3-expression DNA that by itself
As shown in Figure 5B, TL1A treatment increased theminimally activated these pathways (Figure 4A). Under
number of cells expressing IL-2R (CD25) and the levelthese conditions, cotransfection of cDNA encoding full-
of IL-2R (CD122) expression in these cells. We nextlength or the soluble form of TL1A resulted in significant
measured cytokine secretion from these cells and foundNF-B activation. This signaling event was dependent
that both IFN and GMCSF (Figure 5C) were significantlyon the ectopic expression of DR3 and the presence of
induced, whereas IL-2, IL-4, IL-10, or TNF were not (datathe DR3 death domain, as TL1A alone or in combination
not shown). This effect was mostly dependent on anti-with a DD-deleted DR3 did not induce NF-B activation
CD28, as treatment with anti-CD3 and TL1A, in the ab-in these cells. Interestingly, cotransfection of DR3 with
sence of the signal induced by crosslinking CD28, didcDNAs encoding TL1 (full-length or N-terminal 24 aa
not result in significant secretion of cytokines (Figuretruncated) failed to induce NF-B activation, suggesting
5C). The effect that we observed on T cells was specifi-that TL1A and TL1 may utilize distinct receptors and/or
cally mediated by TL1A, as addition of monoclonal neu-transduction pathways and the shared region between
tralizing antibody to TL1A or addition of DR3-Fc or TR6-TL1A and TL1 is not sufficient to mediate NF-B activa-
Fc proteins was able to inhibit TL1A-mediated IFNtion. A similar induction of NF-B activity was observed
secretion (data not shown). TL1A was also tested on awhen recombinant TL1A protein (aa 72–251, from E. coli
variety of primary cells, including tonsil B cells, NK cells,or Flag-tagged from 293T cells) was added to DR3-
monocytes, and endothelial cells, but no significant ac-expressing cells (Figure 4B and data not shown). This
tivity was detected (data not shown), suggesting a spe-induction of NF-B was completely inhibited by the addi-
cific activity of TL1A on T cells.tion of an excess amount of TR6-Fc and partially by the
amount of DR3-Fc used but not by the addition of twice
as much of TNFR1-Fc or Fas-Fc. These results demon- TL1A Induces Caspase Activation in TF-1
strated that TL1A is a signaling ligand for DR3 that in- Cells but Not in T Cells
duces NF-B activation and that TR6 can specifically It has been shown previously that overexpression of
inhibit this event. DR3 in cell lines induces apoptosis (Chinnaiyan et al.,
To study the signaling events mediated by TL1A on 1996; Kitson et al., 1996; Marsters et al., 1996; Bodmer
cells that naturally express DR3, we analyzed various et al., 1997). We then studied the effect of recombinant
cell lines for the expression of DR3 and found that the TL1A on caspase activation and apoptosis in DR3-con-
erythroleukemic cell line TF-1 expressed high levels of taining cells: primary activated T cells and TF-1 cells.
DR3 (data not shown). In addition, DR3 has been shown Activated T cells were incubated with recombinant TL1A
to be upregulated in activated T cells (Screaton et al., or FasL in the presence of cycloheximide (CHX). No
1997; Tan et al., 1997). Therefore, we studied whether induction of caspase activity was detected in TL1A-
TL1A could induce NF-B activation in TF-1 cells and treated T cells, but it was readily measured when cells
in activated T cells. We analyzed the degradation of were triggered with FasL (Figure 6A, left panel), sug-
IB, the cytoplasmic inhibitor of NF-B, and found that gesting that under these experimental conditions, TL1A
in both cell types TL1A rapidly induced the degradation does not activate caspases in T cells (the assay we used
of IB (Figure 4C) and that the TL1A-induced degrada- detects activation of caspases 2, 3, 6, 7, 8, 9, and 10).
tion of IB could be inhibited by increasing amounts In TF-1 cells, in contrast to T cells, TL1A was able to
of TR6-Fc. These results indicate that TL1A can activate induce caspase activation efficiently in the presence of
NF-B in cells expressing endogenous DR3. CHX (Figure 6A, right panel). FasL was also able to
induce caspase activation in this cell line, although less
efficiently than TL1A. Both DR3-Fc and TR6-Fc but not aTL1A Induces IL-2 Responsiveness and Cytokine
Secretion from Activated T Cells control Fc protein efficiently inhibited the TL1A-induced
caspase activation in TF-1 cells (Figure 6B, left panel).As DR3 expression is mostly restricted to lymphocytes
and is upregulated upon T cell activation, we decided A TL1A monoclonal antibody 16H02 was also shown to
completely inhibit this activity (Figure 6B, right panel),to study the biological activity of TL1A on T cells. Re-
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Figure 4. Interaction of DR3 and TL1A Induces NF-B Activation
(A) 293T cells in 6-well plates were cotransfected with 4 NF-B-SEAP reporter (0.1 g), pCMV-lacZ reporter (internal control, 10 ng), pC4:DR3
(5 or 10 ng), or pC4:DR3DD (10 ng). In addition to these constructs, the cells were cotransfected with the indicated forms of either TL1A or
TL1 in pC4. SEAP activity was measured 20 hr later from the supernatant and normalized to -galactosidase activity. Standard deviation was
calculated from triplicate experiments.
(B) 293T cells were cotransfected with 4 NF-B-SEAP reporter (0.1 g), pCMV-lacZ reporter (10 ng), pC4, or pC4:DR3 (5 ng) for 5 hr. Cells
were then treated with the indicated amounts of recombinant TL1A protein from E. coli in combination with the indicated amounts of DR3-
Fc, TR6-Fc, TNFR1-Fc, or Fas-Fc. SEAP activity was measured and displayed as in (A).
(C) PHA-activated primary T cells (left panel) or TF-1 cells (right panel) were treated for the indicated time points with 100 ng/ml of TL1A in
the presence or absence of the indicated amounts of TR6-Fc (left panel). Cell lysates were prepared and analyzed by Western blotting using
a polyclonal antibody to IB. Equal loading was confirmed by reprobing with an anti-PI-3K polyclonal antibody.
confirming that the caspase activation was mediated by lowing TL1A treatment correlated with induction of cell
death, we analyzed both TF-1 cells and primary acti-TL1A. No significant caspase activation was observed in
the absence of CHX in either cell type (data not shown). vated T cells by annexin V and propidium iodide staining.
As shown in Figure 6C, significant apoptosis (annexinTo confirm that the observed caspase activation fol-
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Figure 5. TL1A Increases IL-2 Responsiveness and Induces Cytokine Release in Anti-CD3- and Anti-CD28-Treated T Cells
Human T cells (1  105/ml) in plates coated with suboptimal levels of anti-CD3 (0.3 g/ml) and anti-CD28 (5 g/ml) were either untreated or
treated with rhIL-2 (1 ng/ml) or TL1A (aa 72–251, 100 ng/ml) for 72 hr.
(A) Cells were then incubated with medium alone (RPMI) or with rhIL-2 (1 ng/ml) and pulsed with 0.5 Ci 3H-thymidine for 24 hr to measure
proliferation. Results are expressed as an average of triplicate reactions plus standard error.
(B) Cells were stained with PE-conjugated antibodies against IL-2R (CD25) and IL-2R (CD122).
(C) Human T cells (1  105/ml) were seeded in 24-well plates that had been precoated with either anti-CD3 alone, or anti-CD3 and anti-CD28
as shown above. The cells were then treated with either rhIL-2 (5 ng/ml) or TL1A (100 ng/ml). Supernatants were collected after 3 days and
analyzed for the presence of IFN and GMCSF by ELISA. Results are expressed as an average of triplicate reactions plus standard error.
V/PI positive cells, upper right quadrant of each panel) TL1A Promotes Splenocyte Alloactivation in Mice
To determine if the in vitro activities of TL1A could bewas seen only in TF-1 cells treated with TL1A and CHX
(32.25%). No dramatic apoptosis occurred in T cells 24 reproduced in vivo, a mouse model of acute graft-ver-
sus-host-response (GVHR) was developed in which pa-hr post TL1A treatment in the presence or absence of
CHX. These results are consistent with our measure- rental C57BL/6 splenocytes were injected intravenously
into (BALB/c  C57 BL/6) F1 mice (CB6F1), and thement of caspase activation.
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Figure 6. TL1A Induces Caspase Activation in the Erythroleukemic Line TF-1, but Not in Activated T Cells
(A) Activated T cells (left panel) or TF-1 cells were treated with increasing concentrations of recombinant FasL (aa 130–281) or TL1A (aa
72–251), 0.1 ng/ml–3 g/ml, in the presence of cycloheximide (CHX, 10 g/ml) for 6 hr. Caspase activity was measured as described in the
Experimental Procedures.
(B) TF-1 cells (7.5  104/well) were treated with recombinant TL1A (100 ng/ml) in the presence of CHX for 6 hr. In the left panel, DR3-Fc, TR6-
Fc, and a control Fc protein were added at the indicated concentrations either alone or in combination with TL1A. In the right panel, an anti-
TL1A antibody or an IgG1 control were added at the indicated concentrations in combination with TL1A. Caspase activity was measured as
described in the Experimental Procedures. Results are expressed as an average of triplicate samples plus standard error.
(C) TF-1 cells and activated T cells were treated with CHX (10 g/ml), TL1A (200 ng/ml), or CHX in combination with TL1A for 24 hr. Cells
were then stained for annexin V/propidium iodide and analyzed by FACS. The relative percent of annexin V/PI positive cells is shown.
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Figure 7. TL1A Enhances In Vivo and Ex Vivo Splenic Alloactivation
CB6F1 (H-2bxd) mice were injected intravenously with 1.5  108 of splenocytes from either C57BL/6 (H-2b, alloactivation) or CB6F1 (H-2bxd, F1
to F1) on day 0, followed by a daily intravenous treatment with recombinant TL1A (aa 72–251, 3 mg/kg), heat-denatured TL1A (HD-TL1A), or
buffer for 5 days from day 0 to day 4. Spleen weight (A), spontaneous splenocyte ex vivo proliferation (B), and IFN (C) and GMCSF (D)
production from ex vivo culture were measured. Representative results from one experiment (n  4 mice) were shown as the mean 
 SEM,
and similar results were obtained in two other experiments. The data were analyzed by ANOVA t tests for spleen weight. Kinetic splenocyte
proliferation and cytokine production were analyzed by using a two-way ANOVA model for repeated measurements. Symbols * and ** represent
significant (p  0.05) and highly significant difference (p  0.005), respectively.
recipient’s immune responses were measured. Typical weight (0.22 g). Treatment of allografted CB6F1 mice
with recombinant TL1A protein (aa 72–251) further in-alloactivation results in splenomegaly of the recipient
mice and enhanced proliferation and cytokine produc- creased splenic weight about 50% to a mean value of
0.34 g (Figure 7A). TL1A treatment also significantly en-tion of the splenocytes cultured ex vivo (Via, 1991; Zhang
et al., 2001). The large number of T cells in the spleen hanced ex vivo splenocyte expansion (Figure 7B) and
secretion of IFN (Figure 7C) and GMCSF (Figure 7D).and their expected upregulation of DR3 in response to
alloactivation makes this an ideal model to assess the This effect is dependent on the TL1A protein as heat-
denatured TL1A (HD-TL1A) lost most of these in vivoeffect of TL1A on a defined in vivo immune response.
As shown in Figure 7, 5 day administration of 3 mg/kg/ and ex vivo activities. Thus, TL1A strongly enhances
GVHR in vivo, and this effect is consistent with the ob-day of the recombinant TL1A protein markedly en-
hanced the graft-versus-host responses. The same served in vitro activities.
mean spleen weight (0.095 g) was seen for both naive
mice and mice transferred with CB6F1 syngeneic splen- Discussion
ocytes (Figure 7A). Alloactivation alone (transfer only
C57BL/6 splenocytes into CBF1 mice and treat the mice Death domain-containing receptors have historically
been defined as proteins that can induce apoptotic cellwith buffer only) resulted in a 2.2-fold increase in splenic
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death through activation of caspases. Recent work per- detected by RT-PCR and Taqman (Figures 2B and 2C)
may reflect the small proportion of nuclear RNA in totalformed with TNF, FasL, and Fas (Siegel et al., 2000 and
references within) has shown that while these proteins RNA preparations. Third, TL1A but not TL1 cDNA has
an optimal eukaryotic Kozak sequence (6 AGGAGare potent inducers of cell death they also have the
more subtle ability to act as costimulatory signals during CATGG	4 versus 6 AATGATATGA	4), suggesting
that TL1 may not be properly translated. In line with this,T cell activation. FasL was shown to promote prolifera-
tion and IL-2 secretion from T cells treated with subopti- no activity of the full-length TL1 has been reported, and
the full-length TL1 did not show antiangiogeneic activitymal doses of anti-CD3, whereas Fas-Fc inhibited T cell
costimulation. This positive effect on T cells has been in vivo (Zhai et al., 1999a).
We have found that TL1A functions specifically as afurther confirmed by the studies of the FADD/ mice
(Varfolomeev et al., 1998; Zhang et al., 1998; Newton et T cell costimulator, which is consistent with DR3 being
mainly expressed on activated T cells. The signal in-al., 2001). Cells lacking FADD, which associates with
DD and is required for the recruitment of caspase-8, not duced by TL1A on T cells results in increased respon-
siveness to IL-2 and in the secretion of proinflammatoryonly are impaired in their ability to induce apoptosis but
also exhibit a defect in T cell proliferation in response cytokines. As TL1A production is significantly elevated
in activated endothelial cells, the interaction with DR3to mitogens. This suggests that DD-induced signals may
result in different effects depending on the activation would occur when T cells are recruited to the site of
inflammation and increase their ability to expand andstate of the responding T cell or on the specific stage
of an immune response or of development. Therefore, to secrete proinflammatory cytokines. This, in turn, will
result in recruitment and activation of macrophages andduring the initial stage of an immune response or in the
presence of suboptimal antigen presentation, factors neutrophils. The ability of TL1A to enhance and amplify
an immune response is evident from our in vivo workthat signal through DD-containing receptors may act
as costimulatory signals. In contrast, at the end of an using the acute GVHR model. In this setting, in which a
high proportion of T cells are activated and are thereforeimmune response, they may contribute to the specific
elimination of the excess activated T cells, or they may expected to express DR3, treatment with TL1A resulted
in the exacerbation of the response. We, in fact, foundcontribute to the regulation of negative selection in the
thymus during development. an increase in T cell expansion (increase in splenic
weight and ex vivo proliferation) and in the secretion ofDR3 was initially described as a TNFR capable of
inducing NF-B activation and apoptosis when ectopi- IFN and GMCSF.
Interestingly, we have observed that while TL1A wascally overexpressed in cell lines. TWEAK/Apo3L was
shown to be a ligand for DR3 (Marsters et al., 1998). able to induce NF-B activation and a costimulatory
signal in primary T cells, it did not induce significantNeither others nor ourselves were able to demonstrate
this interaction using similar methods (Schneider et al., caspase activation or apoptosis. In contrast, TL1A was
able to induce caspase activity and apoptosis in the1999; Kaptein et al., 2000; our unpublished data). Re-
cently, a novel TWEAK receptor, TweakR, was identified tumor cell line TF-1, which is consistent with the possi-
bility that binding of TL1A to DR3 may couple to distinct(Wiley et al., 2001). Therefore, the nature of DR3 and
TWEAK interaction remains unclear. signaling pathways in different contexts. The fact that
caspase activation and apoptosis were observed mainlyIn this paper, we describe the identification of a longer
variant of TL1/VEGI, called TL1A, and provide evidence in the presence of CHX indicates that, as seen for other
TNF family members, signaling by TL1A results in athat it is a ligand for both DR3 and TR6. TL1A is ex-
pressed primarily in endothelial cells, and its expression balance between positive and negative effects on cell
viability. Therefore, apoptosis in this cell line can beis highly inducible by TNF and IL-1. As for the relation-
ship between TL1A and TL1, several lines of evidence detected only when protein synthesis is blocked and
proliferative signals are inhibited.strongly suggest that TL1A is the predominant, full-
length gene product for this TNF family member and Although TL1A (aa 72–251) protein exerts potent activ-
ity on activated T cells, we did not observe significantthat TL1 is very likely a cloning artifact. First, TL1A mRNA
is readily detected from endothelial cells, and several antiangiogenic activity of it in both in vitro and in vivo
experiments (our unpublished data). It is known thatEST clones encoding the full-length TL1A exist. In con-
trast, a single TL1 clone with 3.3 kb insert was obtained many antiangiogenic factors are processed protein
products whose full-length proteins have different bio-through cDNA library screening (Zhai et al., 1999a), and
no EST sequence corresponding to the full-length TL1 logical activities. The fact that truncated TL1 proteins,
which correspond to aa 101–251 and 106–251 of TL1Ahas been found from either the public or other data-
bases. Furthermore, we were unable to clone the mouse (Zhai et al., 1999a, 1999b; Yue et al., 1999), have an
antiangiogenic effect is consistent with this notion.or rat TL1 counterparts (L.Z. and P.W., unpublished
data). Second, the human genomic information (Figure Recently, mice with a disrupted DR3 gene have been
described (DR3/ mice; Wang et al., 2001) as having a1B) clearly shows that the TL1A cDNA was derived from
normally spliced, multiexon mRNA, like that of other partial defect in negative selection during thymocyte
development. It will be interesting to see whether TL1ATNF family members. Consistent with this, TL1A has the
characteristics of a full-length type II membrane protein. contributes to the complex regulation of the removal of
autoreactive thymocytes that occurs during develop-The complete matching of TL1 cDNA to a continuous
TL1A genomic DNA region that contains both the introns ment or whether this effect is mediated by another mem-
ber of the TNF family that is able to interact with DR3.and exons with intact consensus splicing sites strongly
suggests that TL1 cDNA was derived from nonspliced/ In addition to TL1A’s binding to DR3, we show that,
as seen in the case of Fas and LIGHT, the decoy receptorincompletely spliced nuclear RNA, a common source
of cloning artifact. The low level of TL1-specific RNA TR6 can compete with DR3 for TL1A binding. Our data
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Recombinant Protein Purificationobtained from the BIAcore analysis and from the inhibi-
Flag fusion proteins were produced from 293T cells by transienttion studies with DR3-Fc and TR6-Fc suggest that TL1A
transfection and purified on anti-Flag M2 affinity columns (Sigma)can bind both receptors with high affinity of the order
according to the manufacturer’s instructions. Receptor proteins with
of what has been previously reported for other members or without Fc fusion were produced from Baculovirus or CHO stable
of the TNFR family and their ligands. TR6 has been cell lines as described (Zhang et al., 2001). Recombinant, untagged
TL1A protein (aa 72–251) was generated and purified from E. coli. Inshown previously to negatively regulate cytotoxic T lym-
brief, E. coli cell extract was separated on an HQ-50 anion exchangephocyte activity in vitro and T cell responses to alloanti-
column (Applied Biosystems) and eluted with a salt gradient. Thegens in acute GVHR in vivo (Zhang et al., 2001). TR6
0.2 M NaCl elution was diluted and loaded on an HQ-50 column,has also been shown to be overexpressed in certain
and the flow-through was collected, adjusted to 0.8 M ammonium
tumors (Pitti et al., 1998; Bai et al., 2000), suggesting that sulfate, and loaded on a Butyl-650s column (Toso Haus). The column
some tumors may escape FasL-dependent cell death by was eluted with a 0.6–0 M ammonium sulfate gradient, and the
fractions containing TL1A protein were pooled and further purifiedexpressing a decoy receptor that blocks FasL. Its ability
by size exclusion on a Superdex-200 column (Pharmacia) in PBS.to bind FasL, Light, and TL1A with high affinity suggests
All recombinant proteins were in trimer form and confirmed by NH2-that it may modulate the duration and the magnitude of
terminal sequencing on an ABI-494 sequencer (Applied Biosystem).an immune response or it might protect tumor cells from
The endotoxin level of the purified protein was less than 10 EU/mg
apoptosis. A careful analysis of TL1A, DR3, and TR6 as measured on a LAL-5000E (Cape Cod Associates).
expression in human diseases may reveal a role for
these molecules in autoimmune, inflammation, or tumor Flow Cytometry, Immunoprecipitation, and Western Blotting
genesis. One million cells, in 0.1 ml of FACS buffer (PBS, 0.1% BSA, and
0.1% NaN3), were incubated with 0.1–1 g of protein or antibody at
room temperature for 15 min. The cells were washed with 3 ml ofExperimental Procedures
FACS buffer, reacted with biotinylated primary antibody, and stained
with PE-conjugated secondary antibody at room temperature forCells, Constructs, and Other Reagents
15 min. Cells were then washed again and resuspended in 0.5 g/All human cancer cell lines and normal lung fibroblasts (HFL-1) were
ml of propidium iodide, and live cells were gated and analyzedpurchased from the American Tissue Culture Collection. Human
on a FACScan using the CellQuest software (BD Biosciences). Forprimary cells were purchased from Clonetics Corp. Cells were cul-
annexin V/PI staining, one million cells in 250 l PBS containingtured as recommended. Human cDNA encoding the full-length TL1,
calcium (BDPharmingen) were incubated with annexin V FITC andTL1A, and DR3; the extracellular domain of TL1 (aa 25–174), TL1A
propidium iodide for 15 min at room temperature in the dark and(aa 72–251), BlyS (aa 134–285), and FasL (aa 130–281); and death
analyzed.domain-truncated DR3 (DR3DD, aa 1–345) and DR5 (DR5DD,
For coimmunoprecipitation studies, 2 g each of purified TNFR-aa 1–321) were amplified by PCR and cloned into the mammalian
Fc proteins was incubated with 1 g of Flag-tagged TL1A, FasL, orexpression vectors pC4 and/or pFLAGCMV1 (Sigma). The extracel-
BlyS protein and 20 l of protein A-Sepharose beads in 0.5 ml oflular domains of human DR3 (aa 1–199), TACI (aa 1–159), HveA (aa
IP buffer (DMEM, 10% FCS, and 0.1% Triton X-100) at 4C for 4 hr.1–192), Fas (aa 1–169), and full-length TR6 (aa 1–300) were each
The beads were then precipitated and washed extensively withfused in-frame, at their C terminus, to the hinge and Fc domain of
PBST buffer (PBS and 0.5% Triton X-100) before being boiled inhuman IgG1 and cloned into pC4. Monoclonal antibody against
SDS-sample buffer.TL1A, 16H02 (IgG1), was raised and purified as described (Kohler
For IB degradation studies, activated T cells or TF-1 cells wereand Milstein, 1975). Stable cell lines expressing pcDNA3.1 vector
treated with 100 ng/ml of TL1A for the indicated time points in thecontrol (Neo) or full-length TL1A were selected in 293F cells in 0.5
presence or absence of the indicated amounts of TR6-Fc. Cellsmg/ml Genticin (Invitrogen).
were then washed and lysed in RIPA buffer. Proteins were separated
on SDS-PAGE (NOVEX), transferred onto PVDF membranes (Milli-Cloning of Human, Mouse, and Rat TL1A cDNA
pore), and immunoblotted with a polyclonal antibody to IB (SantaTL1A was identified from human EST databases. The mouse and
Cruz).rat TL1A cDNA was isolated by low-stringency PCR amplification
from mouse or rat kidney Marathon-Ready cDNAs (Clontech). Each
BIAcore Analysissequence was derived and confirmed from more than two indepen-
Recombinant TL1A (from E. coli) binding to various human TNFdent PCR products.
receptors was analyzed on a BIAcore 3000 instrument. TNFR-Fc
were covalently immobilized to the BIAcore sensor chip (CM5 chip)Quantitative Real-Time PCR (Taqman) and RT-PCR Analysis
via amine groups using N-ethyl-N-(dimethylaminopropyl) carbodii-Total RNA was isolated from human cell lines and primary cells
mide/N-hydroxysuccinimide chemistry. A control receptor surfaceusing TriZOL (Invitrogen). Taqman was carried out in a 25 l reaction
of identical density was prepared with BCMA-Fc that was negativecontaining 25 ng of total RNA, 0.6 M each of gene-specific forward
for TL1A binding and used for background subtraction. Eight differ-and reverse primers, and 0.2 M of gene-specific fluorescence
ent concentrations of TL1A (range: 3–70 nM) were flowed over theprobe. TL1A-specific primers (forward: CACCTCTTAGAGCAGACG
receptor-derivatized flow cells at 15 l/min for a total volume of 50GAGATAA; reverse: TTAAAGTGCTGTGTGGGAGTTTGT; probe: CCA
l. The amount of bound protein was determined during washingAGGGCACACCTGACAGTTGTGA) amplify an amplicon spanning nt
of the flow cell with HBS buffer (10 mM HEPES [pH 7.4], 150 mM257 to 340 of the TL1A cDNA. TL1-specific primers (forward:
NaCl, 3.4 mM EDTA, and 0.005% Surfactant P20). The flow cellCAAAGTCTACAGTTTCCCAATGAGAA; reverse: GGGAACTGATTT
surface was regenerated by displacing bound protein by washingTTAAAGTGCTGTGT; probe: TCCTCTTTCTTGTCTTTCCAGTTGTGA
with 20 l of 10 mM glycine-HCl (pH 2.3). For kinetic analysis, theGACAAAC) amplify nt 17 to 113 of the TL1 cDNA. Gene-specific
on and off rates were determined using the kinetic evaluation pro-PCR products were measured using an ABI PRISM 7700 Sequence
gram in BIAevaluation 3 software using a 1:1 binding model and theDetection System following the manufacturer’s instructions (PE
global analysis method.Corp.). The relative TL1A mRNA level was normalized to the 18S
ribosomal RNA internal control in the same sample.
For RT-PCR analysis, 0.5 g of total RNA was amplified with TL1- T Cell Proliferation Assays
Whole blood from human donors was separated by Ficoll (ICN Bio-(GCAAAGTCTACAGTTTCCCAATGAGAAAATTAATCC) or TL1A-spe-
cific sense primer (ATGGCCGAGGATCTGGGACTGAGC) and an technologies) gradient centrifugation, and cells were cultured over-
night in RPMI containing 10% FCS (Biofluids). T cells were separatedantisense primer (CTATAGTAAGAAGGCTCCAAAGAAGGTTTTATC
TTC) using SuperScript One-Step RT-PCR System (Invitrogen). using the MACS PanT separation kit (Milteny Biotech). The T cell
purity achieved was usually higher that 90%. The cells were seeded-actin was used as an internal control.
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on anti-CD3 (0.3 g/ml, Pharmingen) and anti-CD28 (5.0 g/ml) Thome, M., Bornand, T., Hahne, M., Schroter, M., Becker, K., et al.
(1997). TRAMP, a novel apoptosis-mediating receptor with se-coated 96-well plates at 2  104/well and were incubated with me-
dium alone, 1 ng/ml of IL-2 (R&D Systems), or 100 ng/ml of TL1A quence homology to tumor necrosis factor receptor 1 and Fas(Apo-
1/CD95). Immunity 6, 79–88.(aa 72–251) at 37C. After 72 hr in culture, the cells were either
untreated or treated with 1 ng/ml of IL-2 and pulsed with 0.5 Ci Chinnaiyan, A.M., O’Rourke, K., Yu, G.L., Lyons, R.H., Garg, M.,
of 3H-thymidine for another 24 hr, and incorporation of 3 H was mea- Duan, D.R., Xing, L., Gentz, R., Ni, J., Dixit, V.M. (1996). Signal trans-
sured on a scintillation counter. duction by DR3, a death domain-containing receptor related to
TNFR-1 and CD95. Science 274, 990–992.
Cytokine ELISA Assays for Primary Cells
Connolly, K., Cho, Y.H., Duan, R., Fikes, J., Gregorio, T., LaFleur,1  105 cells/ml of purified T cells were seeded in a 24-well tissue
D.W., Okoye, Z., Salcedo, T.W., Santiago, G., Ullrich, S., et al. (2001).culture plate that had been coated with anti-CD3 (0.3 g/ml) and
In vivo inhibition of fas ligand-mediated killing by TR6, a fas ligandanti-CD28 (5.0 g/ml) overnight at 4C. Recombinant TL1A (aa 72–
decoy receptor. J Pharmacol Exp. Ther. 298, 25–33.251) protein (100 ng/ml) was added to cells, and supernatants were
Eck, M.J., Ultsch, M., Rinderknecht, E., de Vos, A.M., and Sprang,collected 72 hr later. ELISA assays for IFN, GM-CSF, IL-2, IL-4,
S.R. (1992). The structure of human lymphotoxin (tumor necrosisIL-10, and TNF were performed using kits purchased from R&D
factor beta) at 1.9 A˚ resolution. J. Biol. Chem. 267, 2119–2122.Systems. Recombinant human IL-2 (5 ng/ml) was used as a positive
control. All samples were tested in duplicate and results were ex- Kaptein, A., Jansen, M., Dilaver, G., Kitson, J., Dash, L., Wang, E.,
pressed as an average of duplicate samples plus or minus error. Owen, M.J., Bodmer, J., Tschopp, J., and Farrow, S.N. (2000). Stud-
ies on the interaction between TWEAK and the death receptor WSL-
Caspase Assay 1/TRAMP (DR3). FEBS Lett. 485, 135–141.
TF-1 cells or PHA-activated primary T cells were seeded at 75,000
Kitson, J., Raven, T., Jiang, Y.P., Goeddel, D.V., Giles, K.M., Pun,
cells/well in a black 96-well plate with clear bottom (Becton Dickin-
K.T., Grinham, C.J., Brown, R., and Farrow, S.N. (1996). A death-
son) in RPMI medium containing 1% fetal bovine serum (Biowhit-
domain-containing receptor that mediates apoptosis. Nature 384,
taker). Cells were treated with TL1A or FasL in the presence or
372–375.
absence of cycloheximide (10 g/ml) for 6 hr. Caspase activity was
Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cellsmeasured directly in the wells by adding an equal volume of a
secreting antibody of predefined specificity. Nature 256, 503–519.lysis buffer containing 25M DEVD-rodamine 110 (Roche Molecular
Biochemicals) and allowing the reaction to proceed at 37C for 1 to Locksley, R.M., Killeen, N., and Lenardo, M.J. (2001). The TNF and
2 hr. Release of rodamine 110 was monitored with a Wallac Victor2 TNF receptor superfamilies: integrating mammalian biology. Cell
fluorescence plate reader with excitation filter 485 nm and emission 104, 487–501.
filter 535 nm. Marsters, S.A., Sheridan, J.P., Donahue, C.J., Pitti, R.M., Gray, C.L.,
Goddard, A.D., Bauer, K.D., and Ashkenazi, A. (1996). Apo-3, a new
Murine Graft-Versus-Host Reaction member of the tumor necrosis factor receptor family, contains a
CB6F1 (H-2bxd) mice (C57BL/6  BALB/c) were transfused intrave- death domain and activates apoptosis and NF-KB. Curr. Biol. 6,nously with 1.5  108 spleen cells either from C57BL/6 mice (H-2b) 1669–1676.
or from CB6F1 mice on day 0. Recombinant TL1A (aa 72–251) pro-
Marsters, S.A., Sheridan, J.P., Pitti, R.M., Brush, J., Goddard, A.,tein, heat-denatured TL1A (56C for 45 min), or buffer alone was
and Ashkenazi, A. (1998). Identification of a ligand for the death-administered intravenously for 5 days at 3 mg/kg/day starting on
domain-containing receptor Apo3. Curr. Biol. 8, 525–528.the same day as the transfusion. The spleens of the recipient F1
mice were harvested on day 5 and weighed. Single cell suspensions Newton, K., Kurts, C., Harris, A.W., and Strasser, A. (2001). Effects
were prepared for ex vivo assays. of a dominant interfering mutant of FADD on signal transduction in
activated T cells. Curr. Biol. 11, 273–276.
Ex Vivo Mouse Splenocyte Proliferation and Cytokine Assays Pitti, R.M., Marsters, S.A., Lawrence, D.A., Roy, M., Kischkel, F.C.,
Splenocytes from normal and the transfused F1 mice were cultured Dowd, P., Huang, A., Donahue, C.J., Sherwood, S.W., Baldwin, D.T.,
in triplicate in 96-well flat-bottomed plates (4  105 cells/200 l/ et al. (1998). Genomic amplification of a decoy receptor for Fas
well) for 2–4 days. After removing 100 l of supernatant per well on ligand in lung and colon cancer. Nature 396, 699–703.
the day of harvest, 10 l Alamar Blue (Biosource) was added to
Schneider, P., Schwenzer, R., Haas, E., Muhlenbeck, F., Schubert,each well, and the cells were cultured for an additional 4 hr. The
G., Scheurich, P., Tschopp, J., and Wajant, H. (1999). TWEAK cancell number in each well was assessed according to OD590nm minus
induce cell death via endogenous TNF and TNF receptor 1. Eur. J.OD530nm background, using a CytoFluor apparatus (PerSeptive Bio-
Immunol. 29, 1785–1792.systems). Cytokines in the culture supernatant were measured with
Screaton, G.R., Xu, X., Olsen, A.L., Cowper, A.E., Tan, R., McMichael,commercial ELISA kits from Endogen or R&D Systems following the
A.J., and Bell, J.I. (1997). LARD: a new lymphoid-specific deathmanufacturer’s instructions.
domain containing receptor regulated by alternative pre-mRNA
splicing. Proc. Natl. Acad. Sci. USA 94, 4615–4619.Acknowledgments
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